Virtual Library
Start Your Search
R. Yoshino
Author of
-
+
P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.07-004 - Clinical Impact of Post-Progression Survival for Overall Survival in Patients with Sensitive Relapse of Small Cell Lung Cancer (ID 1021)
09:30 - 09:30 | Author(s): R. Yoshino
- Abstract
Background:
The effect of second-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with sensitive relapse of small cell lung cancer (SCLC). But there is no research in this viewpoint. Therefore, we aimed to determine the relationships between progression-free survival (PFS), post-progression survival (PPS) and OS after second-line chemotherapy in this population.
Methods:
Between January 1999 and November 2013, seventy-seven patients with sensitive relapse of SCLC who had received second-line chemotherapy following first-line platinum doublet chemotherapy were analyzed. We retrospectively collected individual data at Gunma Prefectural Cancer Center and National Hospital Organization Nishigunma National Hospital from medical records, and evaluated patient characteristics, treatment data, tumor shrinkage, PFS, PPS and OS.
Results:
The median follow-up time was 13.1 months (range 2.3-80.8 months). The response rate, the disease control rate, median PFS and median OS were 58.4%, 93.5%, 5.1 months and 13.7 months, respectively. The relationships of PFS, PPS and tumor shrinkage with OS were analyzed at the individual level. Spearman rank correlation analysis and linear regression analysis showed that PPS was strongly correlated with OS (r = 0.91, p < 0.01, R [2]= 0.96), PFS was moderately correlated with OS (r = 0.58, p < 0.01, R[2 ]= 0.28), and tumor shrinkage was weakly correlated with OS (r = 0.34, p < 0.01, R[2 ]= 0.12). Using multivariate Cox proportional hazards model with a stepwise regression procedure to explore prognostic factors for PPS, the number of regimens after progression beyond second-line chemotherapy and performance status (PS) at the beginning of third-line treatment were both significantly associated with PPS (p < 0.01).
Conclusion:
PPS has more impact for OS than PFS in patients with sensitive relapse of SCLC. Moreover, this study suggests that subsequent treatment and PS after disease progression following second-line chemotherapy may be important factors that influence OS.
